NasdaqGM:TRVIPharmaceuticals
Did JAMA-Published CORAL Data on Nalbuphine ER Just Shift Trevi Therapeutics' (TRVI) Investment Narrative?
Trevi Therapeutics recently reported that key results from its Phase 2b CORAL trial of oral nalbuphine ER for chronic cough in idiopathic pulmonary fibrosis were published in the Journal of the American Medical Association, with safety outcomes broadly consistent with prior studies.
The data showed similar discontinuation rates between nalbuphine ER and placebo and fewer serious adverse events in the nalbuphine ER group, underscoring a potentially differentiated safety profile.
Next, we’ll...